His early findings in biology have enabled the development of new drug combinations for lymphoma treatment. His clinical trial efforts have improved lymphoma treatments through use of immunotherapy.

Dr. Felipe Samaniego is a Professor in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, and is board-certified in both internal medicine and medical oncology. He earned his medical degree from the Harvard Medical School, and completed his internship and residency at the University of Colorado Health Sciences Center. He then completed a clinical fellowship in Hematology-Oncology at Memorial Sloan-Kettering Cancer Center and a research fellowship in the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development, National Institute of Health.

Dr. Samaniego began his career at The University of Texas MD Anderson Cancer Center in 2000 as Assistant Professor in the Department of Lymphoma/Myeloma where he directed research to understand the science of lymphoma development. His early findings in biology have enabled the development of new drug combinations for lymphoma treatment. His clinical trial efforts have improved lymphoma treatments through use of immunotherapy.

Dr. Samaniego was awarded a Robert Wood Johnson fellowship from 1989 through 2016, has consulted for the Multidisciplinary Research Advisory Committee since 2013, and won the Waun Ki Hong Award for Excellence in Team Science in 2016.